TGA Issues Safety Alert on Unapproved NAD and NMN Medicines in Australia

"The Therapeutic Goods Administration (TGA) has issued a safety alert regarding the sale of medicines in Australia that claim to contain or influence levels of nicotinamide adenine dinucleotide (NAD, NAD+, NADH) or nicotinamide mononucleotide (NMN). These substances are currently not approved for use as ingredients in listed medicines within the country.​ Key Points from the TGA Alert:​ Unapproved Ingredients: NAD and NMN are not permitted ingredients in listed medicines in Australia.​ Compliance Requirements: Medicines supplied, imported, or exported in Australia must be entered in the Australian Register of Therapeutic Goods (ARTG) unless exempted or otherwise authorised by the TGA.​ Advertising Restrictions: Products making claims about NAD or NMN through their name, labelling, or advertising may breach the law, especially if they imply the medicine contains these substances.​ Consumer Guidance: Consumers are advised to check for an AUST L, AUST L(A), or AUST R number on product labels to ensure the medicine is registered or listed in the ARTG.​ The TGA emphasizes that therapeutic goods not included in the ARTG are considered 'unapproved goods' and have not been evaluated for quality, safety, or effectiveness. Consumers are urged to exercise caution when purchasing health products online, as unapproved products may pose health risks."